CDC Advisory Panel Recommends RSV Vaccinations for Pregnant Women
In an effort to protect newborns from respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention (CDC) advisory panel has recently recommended the administration of RSV vaccinations during pregnancy. This advisory comes in light of the approval of Pfizer’s Abrysvo vaccine by the U.S. Food and Drug Administration (FDA) for use in pregnant individuals last month.
The formal approval by the CDC allows Abrysvo to be included in the list of “maternal vaccines” that are recommended before birth. The advisory panel suggests administering Abrysvo between weeks 32 and 36 of pregnancy. This strategic timing aims to provide the best protection to both the mother and the newborn against RSV.
RSV is a common respiratory infection that is especially severe in infants, often leading to hospitalization. In fact, it is responsible for the highest number of hospitalizations among infants. To further combat this illness, Sanofi and AstraZeneca’s nirsevimab, marketed under the brand name Beyfortus, has been approved as an RSV antibody injection for both infants and young children.
The administration of nirsevimab is advised just before or during the RSV season, which typically runs from October to March. By providing protection during this critical period, healthcare professionals hope to significantly reduce the number of RSV-related hospitalizations among young children.
It is crucial for parents to consult with their doctors regarding the available options for protecting their children from RSV illness. The CDC’s approval of Abrysvo and GSK’s Arexvy vaccine for adults aged 60 and older in June emphasizes the importance of vaccinating against RSV across different age groups. Notably, Arexvy became the first RSV vaccine to receive FDA approval the previous month.
According to the CDC, thousands of children under the age of 5 and individuals over the age of 65 are hospitalized annually with RSV in the United States. By expanding the availability and recommendation of RSV vaccinations, healthcare professionals hope to mitigate the impact of this respiratory illness on vulnerable populations.
Through these recent developments in RSV vaccinations, healthcare providers are working diligently to protect individuals of all ages from the harmful effects of this prevalent virus. Stay informed, consult your healthcare provider, and take the necessary steps to safeguard the health of yourself and your loved ones.
